ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating innovative medicines for cancer patients with critical needs. It specializes in developing targeted therapies, particularly for non-small-cell lung cancer (NSCLC) and other solid tumors. Among its key projects is Furmonertinib, a promising drug in phase 3 trials aimed at NSCLC. Founded in 2021 and headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma is also known for its strategic partnership with Aarvik Therapeutics Inc., enhancing its development capabilities.
Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event…
Warren Buffett has purchased more of his favorite energy stock. Other notable insider buying in the past week came from CEOs.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
